HRS-4729 vs UBT251

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline

HRS-4729

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 2 in Obesitypeptide
Weak signal

NCT06762600 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: March 2027 · NCT07690826 (registry estimate)

Reported efficacy

Adverse events (AEs) (Screening period up to day 43.): In the multiple-dose portion at Week 12, participants receiving multiple doses of 12 mg HRS-4729 achieved a mean weight loss of up to 16.0% from baseline, compared to 5.4% with placebo. HRS-4729 demonstrated linear pharmacokinetics with a half-life of approximately 4 to 5 days, supporting once-weekly dosing, and safety and tolerability consistent with GLP-1-based treatments. (not_applicable)

Result source: NCT06762600

UBT251

Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)

Phase 3 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07785934 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-4729UBT251
Body weight, % change—Not reported—Trial running · NCT07806851
Weight loss of 5% or more—Not reported—Trial running · NCT07806851
Weight loss of 10% or more—Not reported—Trial running · NCT07806851
Waist circumference, change (cm)—Not reported—Trial running · NCT07806851

Body weight, % change

HRS-4729
—Not reported
UBT251
—Trial running · NCT07806851

Weight loss of 5% or more

HRS-4729
—Not reported
UBT251
—Trial running · NCT07806851

Weight loss of 10% or more

HRS-4729
—Not reported
UBT251
—Trial running · NCT07806851

Waist circumference, change (cm)

HRS-4729
—Not reported
UBT251
—Trial running · NCT07806851
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-4729: no structured comparison results are available for Obesity.

UBT251: no structured comparison results are available for Obesity.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-4729's landscape · UBT251's landscape